Retraction notice to “Silencing STAT3 enhances sensitivity of cancer cells to doxorubicin and inhibits tumor progression” [Life Sci. 275 (2021) 119369]
Navneet Joshi(Mody University of Science and Technology), Farhad Jadidi‐Niaragh(Tabriz University of Medical Sciences), Farnaz Hajizadeh(Tabriz University of Medical Sciences), Ehsan Ansari Dezfouli(Technical University of Denmark), Vahid Karpisheh(Tabriz University of Medical Sciences), Sanam Dolati(Tabriz University of Medical Sciences), Mohsen Nabi‐Afjadi(Tarbiat Modares University), Mehdi Yousefi(Tabriz University of Medical Sciences), Seyedeh Mahboubeh Mousavi(Tabriz University of Medical Sciences), Mohammad Hojjat‐Farsangi(Karolinska University Hospital), Hadi Hassannia(Mazandaran University of Medical Sciences), Angelina Olegovna Zekiy(Sechenov University), Ata Mahmoodpoor(Tabriz University of Medical Sciences), Hamed Mohammadi(Tehran University of Medical Sciences)
Cited by 0
Related Papers
Nanoparticles and targeted drug delivery in cancer therapy
|Immunology Letters|2017|507
Clinical application of mesenchymal stem cell in regenerative medicine: a narrative review
|Stem Cell Research & Therapy|2022|404
The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer
|Biomedicine & Pharmacotherapy|2018|312
RETRACTED ARTICLE: Mesenchymal stem/stromal cells as a valuable source for the treatment of immune-mediated disorders
|Stem Cell Research & Therapy|2021|275
The paradox of Th17 cell functions in tumor immunity
|Cellular Immunology|2017|222